跳至主要内容
临床试验/NCT00084539
NCT00084539已完成2 期

Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost in Early Stage Breast Cancer

Fox Chase Cancer Center2 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2003年11月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
78
试验地点
2
主要终点
Acute toxicity by CTCAE at 6 weeks

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Hypofractionated (fewer treatments than in standard radiation therapy) intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) with incorporated boost (an increase in the amount of radiation given during treatment) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well adjuvant hypofractionated intensity-modulated radiation therapy with incorporated boost works in treating patients with early-stage breast cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the toxicity associated with adjuvant hypofractionated intensity-modulated radiotherapy using an incorporated boost in patients with early-stage breast cancer.

Secondary

  • Determine the long-term cosmetic result and quality of life of patients treated with this regimen.
  • Determine the long-term local control in patients treated with this regimen.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Acute toxicity by CTCAE at 6 weeks

时间窗: 6 weeks

次要结局

  • Quality of life as measured by the Breast Cancer Treatment Outcome Scale (BCTOS) every 6 months for 5 years(every 6 months for 5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验